CLINUVEL considers Nasdaq listing and ASX exit as US relocation gathers pace
CLINUVEL Pharmaceuticals Ltd has confirmed its Board of Directors is considering a transaction that would list all of the company’s ordinary shares on the Nasdaq (Global Select Market) under a foreign holding company and delist from the ASX. The proposal reflects the biopharmaceutical company’s deepening operational presence in the United States.
Importantly, this is a Board consideration and not a final decision. Due diligence continues, and any transaction would remain subject to shareholder, Court, ASX and regulatory approvals.
Alongside the listing consideration, CLINUVEL confirmed its operational headquarters will relocate to the United States, effective 1 January 2027. The company is already dual-listed, trading under ASX: CUV, Nasdaq: CUVL and Börse Frankfurt: UR9.
Under the proposed structure, existing shareholders would receive ordinary shares representing an “equivalent proportionate economic interest” in the Nasdaq-listed entity. Shareholders need to take no action at this time, and all existing security holdings are unaffected.
When big ASX news breaks, our subscribers know first
What the proposed transaction involves
The transaction would be implemented by way of a Scheme of Arrangement under Part 5.1 of the Corporations Act 2001 (Cth), a mechanism subject to both shareholder and Court approval. A foreign holding company (“New HoldCo”) would become the new parent of the CLINUVEL Group.
Current CLINUVEL shareholders would receive ordinary shares in New HoldCo representing an “equivalent proportionate economic interest” to their existing interest, subject to the rounding of fractional entitlements. New HoldCo would then seek to list on the Nasdaq (Global Select Market).
The key features of the proposed transaction include:
-
Scheme of Arrangement under Part 5.1 of the Corporations Act 2001 (Cth)
-
New foreign HoldCo becomes the group parent
-
Shareholders receive an equivalent proportionate economic interest in New HoldCo
-
Nasdaq (Global Select Market) listing sought
-
ASX delisting and Börse Frankfurt trading discontinuation
The proposal represents a structural realignment intended to match the listing location with where the business increasingly operates. No share price, exchange ratio or valuation has been disclosed.
Why CLINUVEL is looking to the United States
CLINUVEL’s strategic rationale rests on its existing operational footprint. The company’s main research and development activities are currently undertaken in Singapore, while its commercial and clinical operations are managed from the United Kingdom, European Union and United States.
With the new US headquarters taking effect from 1 January 2027, management has framed the proposed Nasdaq listing as reflecting the growing significance of the company’s US operations. The United States is described as the largest global market in scientific innovation.
The CLINUVEL US headquarters relocation, effective 1 January 2027, is accompanied by a global workforce reduction of approximately 10-20%, with the company framing the cuts as a realignment of operating expenditure rather than a distress response, funded from a $233 million cash position with zero debt.
The financial logic is drawn directly from the company’s revenue base. All of CLINUVEL’s revenues are generated in Europe and North America, its future pharmaceutical activities are targeted at North America, and the majority of its senior executives are based outside Australia.
The CLINUVEL profitability streak, which extended to 9.5 consecutive years as of the H1 FY26 results, places the company in fewer than 4% of global biotechs operating profitably, a financial foundation that management has cited as enabling the self-funded transition to a US-listed structure.
Dr Philippe Wolgen, Chief Executive Officer
“We have methodically and gradually worked towards the moment whereby the Company has reached maturity of its operations, R&D capabilities and balance sheet to support consideration of gaining access to a larger life sciences capital market.”
“All of CLINUVEL’s revenues are generated in Europe and North America, our future pharmaceutical activities targeted are on North America, and the majority of our senior executives based outside Australia. We believe it is thus appropriate to consider whether a U.S. focused group and Nasdaq listing better align with the Company’s future operations and strategic direction.”
The table below summarises how the company’s current operational footprint aligns with the proposed structure.
| Function | Current Location | Strategic Direction |
|---|---|---|
| Research & Development | Singapore | Currently undertaken |
| Commercial & Clinical | UK, EU, US | US-weighted |
| Headquarters | Melbourne (Australia) | US, from 1 Jan 2027 |
| Revenue generation | Europe & North America | North America focus |
| Primary listing | ASX (+ Nasdaq, Frankfurt) | Nasdaq Global Select Market |
Understanding a Nasdaq listing and Scheme of Arrangement
The Nasdaq Global Select Market is a segment of the US Nasdaq exchange. A biopharmaceutical company may seek access to this market to gain access to a larger life sciences capital market.
A Scheme of Arrangement is a Court-approved and shareholder-approved mechanism used to restructure a company’s ownership. Under a foreign HoldCo structure, existing shareholders effectively swap their current holdings for shares in the new parent company, retaining an equivalent proportionate economic interest.
For investors, the potential trade-off is a familiar one. A US listing may offer exposure to larger capital pools, balanced against the loss of ASX and Börse Frankfurt trading access.
What happens next for shareholders
The proposal remains at an early stage. No final Board decision has been made, and due diligence continues with input from global counsel and auditors. Any decision to proceed would be subject to finalisation of the transaction structure and documentation, followed by the required shareholder, Court, ASX and regulatory approvals.
Shareholders do not need to act now, and existing holdings are unaffected. Further information, including detail on the discontinuation of the ASX listing and German trading through Börse Frankfurt, will be provided to shareholders in due course.
The necessary conditions and approvals include:
- Completing due diligence with global counsel and auditors
- Finalising the transaction structure and documentation
- Reaching a final Board decision
- Obtaining shareholder and Court approval for the Scheme of Arrangement
- Securing ASX and regulatory approvals while pursuing the Nasdaq listing
With no listing timeline disclosed, the next concrete milestone remains the relocation of CLINUVEL’s operational headquarters to the United States on 1 January 2027.
Don’t Miss the Next Healthcare Sector Shake-Up
Breaking ASX healthcare news lands in your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who rely on Big News Blast for FREE real-time alerts the moment market-moving announcements hit. Click the “Free Alerts” button to stay ahead before the market moves.